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clinical trials for the treatment of patients with advanced solid
tumors. Mechanistically, these mRNA-lipoplex vaccines are
characterized by the induction of type I interferon (IFN)
centered innate responses. Earlier studies have identified type I
IFNs as major regulators of the T cell response instigated by
mRNA-lipoplex vaccines. However, stimulatory or, in contrast,
profound inhibitory effects of type I IFNs were described de-
pending on the study. In this mouse study, we demonstrated
that the opposing roles of type I IFN signaling on the magnitude
of the vaccine-evoked T cell responses is dependent on the route
of mRNA-lipoplex administration and is regulated at the level of
the T cells rather than indirectly through modulation of den-
dritic cell function. This study helps to understand the double-
edged sword character of type I IFN induction upon mRNA-
based vaccine treatment and may contribute to a more rational
design of mRNA vaccination regimens.
INTRODUCTION
In-vitro-transcribed mRNA has emerged as a promising new class of
biologics in a wide variety of treatment areas.1–10 In-vitro-transcribed
mRNA indeed constitutes an extremely versatile platform, enabling
one to encode any therapeutic protein of interest, which can be ex-
pressed in the cytosol, as amembrane protein, or secreted in the extra-
cellular environment. In the context of vaccination, mRNA vaccines
have shown great potential to evoke cytolytic CD8+ T cells, as well as
antibody responses, making them particularly attractive modalities
for therapeutic cancer vaccine development.11–14
mRNA is a hydrophilic, negatively chargedmacromoleculewith limited
capacity to cross the hydrophobic membranes of cells. Therefore, pack-
aging the mRNA in a nanoparticle format that enables efficient uptake
by cells and endosome-to-cytosol translocation is key to success.15,16
mRNA-lipoplexes, in which mRNA is electrostatically complexed into
liposomes that contain a cationic lipid and a fusogenic helper lipid,
are currently explored as therapeutic cancer vaccines in several clinical
studies (e.g., ClinicalTrials.gov: NCT02410733 and NCT02316457).
Subcutaneous (s.c.) immunization with mRNA-lipoplexes composedMolecular Therap
This is an open access article under the CC BY-NC-of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)/dioleoyl-
phosphatidylethanolamine (DOPE) was first demonstrated to yield
cytolytic T cell responses in mice, albeit of limited potency and magni-
tude.17,18 More recently, Kranz et al.4 reported that intravenous (i.v.)
mRNA-lipoplex vaccination represents a superior route of administra-
tion compared with the s.c. or intradermal (i.d.) route, with the induc-
tion of high-level T cell responses that showed profound antitumor ef-
ficacy in syngeneic tumor models. These promising efficacy data,
alongside adequate safety in non-human primate studies, have fueled
several clinical studies in patients with metastatic melanoma (Clinical-
Trials.gov: NCT03897881 and NCT03480152) and non-small cell lung
cancer (ClinicalTrials.gov: NCT03908671 and NCT03948763). Induc-
tion of strong T cell responses was also reported by Broos et al.19
upon i.v. immunization of mice with alternative but closely related
mRNA-lipoplexes based onRNAiMAX. In all of these studies, type I in-
terferons (IFNs) were identified as the most prominent cytokines eli-
cited early upon mRNA-lipoplex administration.4,17–19
Type I IFNs constitute a large family of cytokines consisting of the
well-studied IFN-a and IFN-b and the less characterized IFN-ε,
IFN-t, IFN-k, IFN-u, IFN-d, and IFN-z. Upon recognition of micro-
bial nucleic acids by innate RNA sensors, type I IFN production is
initiated.20 Subsequently, these type I IFNs bind to the heterodimeric
IFN-a/b receptor (IFNAR) complex consisting of the IFNAR1 and
IFNAR2 chains.21 An exception to this is IFN-b that was reported
to also bind to IFNAR1 homodimers. Upon IFNAR signaling, the Ja-
nus kinase (JAK)/signal transducer and activator of transcription
(STAT) pathway is activated.21,22
In-vitro-transcribed mRNA triggers the same innate RNA sensors
that have evolved to recognize microbial RNAs, hence evoking the
type I IFN signature that is typically associated with viral infections.y: Nucleic Acids Vol. 22 December 2020 ª 2020 The Author(s). 373
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic AcidsType I IFNs are pleiotropic antiviral cytokines that can affect nearly
every step of the immune response to mRNA vaccination, ranging
from mRNA expression over dendritic cell (DC) activation to T cell
differentiation. Not surprisingly, type I IFNs hence were found to
be central mediators of T and B cell response evoked to mRNA vac-
cines. More recently, Zhong et al.23 found that type I IFNs elicited af-
ter i.d. vaccination with a self-amplifying RNA against Zika virus
negatively modulated the B and T cell responses.
In the context of mRNA lipoplex vaccination, both beneficial and
detrimental effects of type I IFN on the vaccine-elicited T cell
response were reported. Type I IFNs were reported to be important
for the induction of antigen-specific T cell responses following i.v.
administration of mRNA-lipoplex vaccines,4,19 yet in sharp contrast,
type I IFN signaling was associated with potent suppression of T cell
responses upon s.c. and i.d. mRNA vaccination.17,24
With the current study, we intend to shed light on the mechanisms
underlying this apparently opposing role of type I IFN in the context
of systemic versus topical immunization with mRNA-lipoplexes. We
first confirmed the opposing roles of type I IFN on T cell immunity
upon i.v. versus s.c. administration, using the same mRNA and lipo-
plexes (DOTAP/DOPE and RNAiMAX) as described in earlier
studies, thereby excluding lab-to-lab variability as a potential under-
lying cause of these apparently conflicting reports. We next investi-
gated the contribution of IFNAR signaling on the level of the DCs
or T cells by using mice that lack the type I IFN receptor (IFNAR)
selectively in CD11c+ cells (CD11c-Cre+/IFNARfl/fl mice) or
T cells (CD4-Cre+/IFNARfl/fl mice). We were able to demonstrate
that IFNAR signaling exerts its inhibitory versus stimulatory role
directly at the level of the T cells and not indirectly by modulating an-
tigen expression and function of DCs.
RESULTS
Induction of Type I IFN Reporter Gene Expression upon Local
and Systemic Injection of Two Types of mRNA-Lipoplexes
To formally exclude that the reported discrepancies on the role of type I
IFN were caused by differences in mRNA format or lipoplex
manufacturing, we performed a head-to-head comparison of s.c. and
i.v. vaccination using mRNA from a single commercial provider and
using identically prepared batches of mRNA-lipoplexes (both DO-
TAP/DOPE and RNAiMAX). To shed light on the seemingly opposing
roles that type I IFN can exert on the magnitude of the T cell response
following immunization with mRNA-lipoplexes, we first analyzed the
intensity and kinetics of the induction of a reporter gene that is under
the transcriptional control of the IFN-b promoter for the two kinds of
lipoplexes (DOTAP/DOPE versus RNAiMAX) and two delivery routes
(s.c. and i.v.) using an IFN-b reporter mouse strain25 (Figures 1A and
1B). Heterozygous reportermice (IFN-b+/Db-luc) were used to retain the
feedforward loop of type I IFN production. Ten micrograms of Clean-
Cap OVA mRNA was packed with either DOTAP/DOPE or RNAi-
MAX and injected i.v. or s.c. at the tail base of the mice. Regardless
of the particle type used and the route of mRNA-lipoplex administra-
tion, we observed expression of the reporter gene that peaked 6–24 h374 Molecular Therapy: Nucleic Acids Vol. 22 December 2020after injection (Figures 1C and 1D). After s.c. injection the RNAiMAX
formulation tended to be more innate stimulating than the DOTAP/
DOPE formulation.
The Route of Administration Governs the Impact of Type I IFN on
the Induced T Cell Response
The impact of type I IFN signaling on the magnitude and function-
ality of the generated T cell response was assessed through compara-
tive immunization studies in wild-type C57BL6 mice and in mice
lacking the common IFNAR1 (IFNAR/).
Mice were immunized with mRNA encoding ovalbumin (OVA) in a
prime-boost-schedule. mRNAs contained a Cap1 structure through
co-transcriptional incorporation of CleanCap (TriLink). No modified
nucleotides were incorporated. Two weeks after the second immuni-
zation, the T cell responses were analyzed using an IFN-g enzyme-
linked immunosorbent spot (ELISpot) assay, an intracellular cytokine
staining (ICS) specific for IFN-g, and an in vivo killing assay.
As depicted in Figures 2A and 2B, IFN-g-secreting cells were
undetectable in splenocytes isolated from wild-type mice after s.c. im-
munization with DOTAP/DOPE or RNAiMAX-based lipoplexes.
Conversely, IFNAR/ mice displayed high numbers of OVA-spe-
cific IFN-g-secreting T cells after s.c. immunization with both lipo-
plexes. These results confirm the profound inhibitory effect of type
I IFNs on T cell responses induced by mRNA-lipoplexes as reported
by De Beuckelaer et al.17 and Pollard et al.18 Upon i.v. administration
of OVA encoding mRNA-lipoplexes, high numbers of OVA-specific
CD8+ T cells were readily detectable. IFNAR deficiency in this case led
to a partial reduction in the magnitude of the evoked response, indi-
cating a positive impact of type I IFN signaling upon i.v. mRNA-lip-
oplex administration and in line with previous reports of Broos et al.19
and Kranz et al.4 (Figures 2A and 2B).We further analyzed the impact
of IFNAR signaling on the cytolytic capacity of the evoked CD8+
T cell response for the different immunization routes and mRNA lip-
oplexes using an in vivo killing assay.26 Whereas loss of type I IFN
clearly enabled the cytolytic capacity of the induced T cells in the
case of s.c. immunization, its loss was associated with a reduced
T cell stimulatory effect in the case of i.v. immunization (Figure 2C).
Taken together, these experiments confirm that the differential
impact of type I IFN on the T cell response4,17,19 primarily depends
on the route of the mRNA-lipoplex administration and is not caused
by lab-to-lab variability nor by the type of lipoplex.
IFNAR Signaling in T Cells Interferes with T Cell Immunity upon
s.c. Immunization
As shown above, in the case of s.c. delivery, type I IFN signaling clearly
exerts a negative impact on the magnitude and functionality of the
T cell response. Theoretically, type I IFN could affect T cell immunity
directly at the level of the T cell by regulating T cell differentiation and
survival, or indirectly at the level of DCs by regulating antigen presen-
tation.27–31 To unravel whether this negative role of type I IFN is deter-
mined by IFNAR signaling at the level of DCs, T cells, or both, we
Figure 1. mRNA-Lipoplexes Induce a Type I IFN Response In Vivo Independently of the Used Particle or Route of Administration
(A) Tabular view of the four possible combinations of mRNA-particles and route of immunization that were tested based on the reports of Broos et al.,19 Kranz et al.,4 and De
Beuckelaer et al.17 (B) A schematic representation of the IFN-b reporter transgene. By using a Cre-Lox system, themyc-tagged luciferase gene is under the control of the IFN-
b promoter in one allele of the IFN-b gene.25 (C and D) IFN-b+/Db-luc mice were injected s.c. or i.v. with 10 mg CleanCap OVA mRNA wrapped in DOTAP/DOPE or RNAiMAX
lipoparticles. (C) Whole-body luminescence was measured 24 h after injection of mRNA-lipoplexes. (D) Whole-body luminescence was measured at 0, 6, 24, 48 or 72 h after
injection of mRNA-lipoplexes. Data are shown as a mean ± SD of five mice. The dotted line represents the background intensity.
www.moleculartherapy.orgperformed comparative immunization in wild-type mice and in mice
lacking IFNAR selectively in CD11c+ cells (CD11c-Cre+/IFNARfl/fl
mice) or T cells (CD4-Cre+/IFNARfl/fl mice). An identical prime-
boost immunization regimen was performed as described above.
Similar towild-typemice (shown in Figure S1), CD11c-Cre+/IFNARfl/fl
mice showed very weak antigen-specific T cell responses in response to
s.c. vaccination, meaning that the impact of IFNAR signaling at the
level of the DC is fairly limited (Figures S1 and 3). In contrast,
CD4-Cre+/IFNARfl/flmice displayed strongly elevated T cell responses
compared with wild-type mice (Figures S1 and 3). Taken together, these
data indicate that upon s.c. administration of mRNA-lipoplexes, type I
IFN signaling hampers the generation of antigen-specific T cells at the
level of the T cell.
IFNAR Signaling in T Cells Promotes T Cell Immunity upon i.v.
Delivery
In contrast with s.c. immunization, type I IFN signaling promotes
T cell responses following i.v. administration of mRNA-lipoplexes.To address whether these stimulatory effects are situated at the level
of the DC and/or T cell, we now performed comparative immuniza-
tion experiments for the i.v. vaccination setting. This comparison re-
vealed that, irrespective of the type of particle (DOTAP/DOPE versus
RNAiMAX), loss of IFNAR signaling in DCs did not abrogate the
T cell response (Figures 4 and S2).19 In contrast, loss of IFNAR
signaling in T cells significantly reduced the magnitude and cytolytic
functionality of evoked CD8 T cell responses. This shows that type I
IFN, also after i.v. mRNA lipoplex injection, mainly acts at the level of
the T cell and not at the level of the DC (Figures 4 and S2).
DISCUSSION
mRNA-lipoplex vaccines have emerged as appealing therapeutic mo-
dalities to treat patients with advanced cancers.1–3,32,33 Earlier studies
in mice demonstrated that s.c. administration of mRNA-lipoplexes
elicits antigen-specific CD8+ T cells of limited strength and antitumor
efficacy.17 More recently, two independent studies showed that i.v.
administration of mRNA-lipoplexes resulted in high-magnitude
T cell responses and prominent antitumor efficacy, a finding thatMolecular Therapy: Nucleic Acids Vol. 22 December 2020 375
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www.moleculartherapy.orgresulted in several early-stage clinical studies and a phase II trial
(ClinicalTrials.gov: NCT03815058) with mRNA-lipoplexes to
address safety and efficacy.4,19 Mechanistically, this superior efficacy
of i.v. vaccination has been attributed to a systemic targeting of DCs in
the spleen, alongside the establishment of a type I IFN centered innate
response. Interfering with type I IFN signaling by using IFNAR-defi-
cient mice34 or by antibody-mediated IFNAR blockade indeed re-
sulted in a partial reduction of the magnitude and functionality of
the vaccine-elicited CD8 T cell response.4,19 Surprisingly, following
s.c. administration of mRNA-lipoplexes, our group previously found
that loss of type I IFN signaling was associated with a strongly
enhanced cytolytic CD8 T cell response.17,35 Taken together, these re-
ports suggested a complex and opposing role of type I IFN in the regu-
lation of T cell immunity to mRNA vaccines, urging further studies to
better comprehend the contribution of type I IFN actions in inducing
a cellular immune response by a mRNA-lipoplex vaccine.
To exclude the possibility that the discrepancies between these studies
originate from differences in either mRNA, lipoplex format, or
experimental conditions, we performed head-to-head comparative
immunization experiments in wild-type and IFNAR/ mice using
identical mRNA and two types of lipoplex formulations for each im-
munization route. These experiments confirmed previous re-
ports,4,17,19 with profound inhibitory effect of type I IFNs signaling
upon s.c. administration and stimulatory actions following i.v.
administration of the mRNA-lipoplex vaccines. Type I IFNs can
affect T cell responses directly, through IFNAR triggering on
T cells, and also indirectly, by modulating antigen expression and an-
tigen presentation by DCs.27–31
By comparing immunization studies in mice that are selectively defi-
cient in IFNAR signaling in T cells (CD4-Cre+/IFNARfl/flmice) or in
CD11c+ cells (CD11c-Cre+/IFNARfl/fl mice), we were able to
demonstrate that type I IFN signaling regulates the mRNA-lipo-
plex-induced T cell response predominantly at the T cell level.
Selective IFNAR deficiency in T cells reduced the strength of the vac-
cine-elicited T cell response to a similar extent as full IFNAR defi-
ciency upon i.v. mRNA-lipoplex administration. In this case, type I
IFNs thereby act as “signal 3” cytokines that promote T cell differen-
tiation into cytolytic effectors.29,36,37 However, upon s.c. administra-
tion, IFNAR deficiency in T cells instead dramatically expanded the
strength of the T cell response, showing that the anti-proliferative/
pro-apoptotic functions of type I IFN on T cells prevail in this case.
This opposing role of type I IFN on T cell function is reminiscentFigure 2. The Outcome of Type I IFN Signaling on the Induced T Cell Response
Wild-type and IFNAR/ mice were immunized s.c. or i.v. with 10 mg CleanCap OVA mR
the induced T cell response was determined. (A and B) Spleens were isolated, and the sp
specific interferon-g (IFN-g)-producing splenocytes (SFCs) was determined by enzyme
dividual mice (n = 8 per group) and the mean. (B) OVA-specific T lymphocytes in the sple
intracellular staining against IFN-g. Data in the graph represent individual mice (n = 8 per
(CFSElow) or OVA peptide (CFSEhigh) were adoptively transferred in a 1:1 ratio to the indic
flow cytometry. Data in the top right graph represent individual mice (n = 8 per group) and
on datasets were performed by Mann-Whitney test. Asterisks indicate statistical signifiof what has been reported in the context of viral infections.38 Mech-
anistic studies have revealed that the relative kinetics of IFNAR trig-
gering to T cell receptor (TCR) activation control T cell fate upon type
I IFN exposure. If IFNAR triggering precedes TCR, a pro-apoptotic
and anti-proliferative transcription program entails. Such a chain of
events is likely to unfold in the case of s.c. mRNA-lipoplex immuni-
zation, in which type I IFN production occurs almost instantly, yet
TCR triggering is delayed until DCs that have internalized the
mRNA-lipoplexes have reached the draining lymph nodes from the
peripheral tissue. If, however, IFNAR and TCR signaling coincide,
type I IFNs act as stimulatory cytokines that promote T cell prolifer-
ation, differentiation, and survival. Upon systemic administration,
mRNA expression immediately takes place in DCs present in the
spleen,19,39 the large secondary lymphoid organ where large numbers
of T cells reside, thereby bypassing the need for time-dependent DC
migration. Therefore, concomitant TCR activation and type I IFN
signaling now can occur in T cells, evoking a T cell-stimulatory tran-
scriptional program. Remarkably, Honke et al.40 showed that expres-
sion of the gene encoding the protein Usp18 in macrophages led to
lower type I IFN responsiveness. Consequently, expression of
USP18 in certain immune cells could also be a possible explanation
for the success of the i.v. administration route of non-modified
mRNA lipoplexes in spite of type I IFN induction.
In summary, this study contributes to our understanding on the regu-
lation of T cell responses directed against mRNA-encoded antigens
that can be elicited by mRNA-lipoplex vaccines. Moreover, these
findings enable a more rational design of safer and potentially more
potent mRNA-lipoplex vaccines, through the targeted modulation
of type I IFN signaling. Despite the strong immunogenicity observed
in rodents upon i.v. vaccination, systemic administration of mRNA-
lipoplexes comes with an increased safety risk, including potential
infusion reactions, liver toxicity, and systemic inflammatory re-
sponses. Local administration would be a safer bet, provided it can
approach the high immunogenicity seen after i.v. administration.
Given the strong T cell responses we have observed upon s.c. immu-
nization of CD4-Cre+/IFNARfl/fl mice, strategies that interfere with
type I IFN induction and/or with IFNAR signaling at the level of
T cells could become an appealing avenue to reach this goal.
MATERIALS AND METHODS
Mice
Seven- to ten-week-oldmice, all onC57BL/6 background, were used for
all experiments.Wild-type C57BL/6 mice were purchased from JanvierDepends on the Route of mRNA-Lipoplex Administration
NA-lipoplexes (DOTAP/DOPE or RNAiMAX). Two weeks after the last immunization,
lenocytes were stimulated in vitrowith OVA peptide for 16 h. (A) The number of OVA-
-linked immunosorbent spot (ELISpot). Data in the graph on the right represent in-
ens of mRNA-lipoplex-immunized mice were measured by flow cytometry using an
group) and the mean +/ SD. (C) Amixture of CFSE-labeled cells pulsed with control
ated mRNA-lipoplex-immunized mice. Specific killing was measured 2 days later by
themean. Representative flow cytometry plots are shown below. Statistical analyses
cance (**p < 0.05, ***p < 0.01).
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Figure 3. Type I IFN Signaling on T Cells Suppresses
the Overall Outcome of the T Cell Response upon
s.c. Delivery of mRNA-Lipoplexes
CD11c-Cre+/IFNARfl/fl and CD4-Cre+/IFNARfl/fl mice
were immunized s.c. with 10 mg CleanCap OVA mRNA-
lipoplexes (DOTAP/DOPE or RNAiMAX). (A and B) Two
weeks after the last immunization the induced T cell re-
sponses were determined. Spleens were isolated, and
the splenocytes were stimulated in vitro with OVA pep-
tide for 16 h. (A) The number of OVA-specific IFN-g-
secreting splenocytes was determined by ELISpot. Data
represent individual mice and the mean (five or six mice
per group). (B) OVA-specific T lymphocytes were
measured by flow cytometry using intracellular staining
for IFN-g. Data represent individual mice and the
mean +/ SD (five or six mice per group). (C) A mixture
of CFSE-labeled cells pulsed with control (CFSElow) or
OVA peptide (CFSEhigh) was adoptively transferred in a
1:1 ratio to mRNA-lipoplex-immunized mice (s.c. route).
Specific killing was analyzed 2 days later by flow
cytometry. Data represent individual mice and the
mean +/ SD (five or six mice per group).
Molecular Therapy: Nucleic Acids(Le Genest Saint Isle, France). IFN-b reporter mice25 and knockout
strains, including mice lacking the common IFNAR1 (IFNAR/),
CD11c-Cre+/IFNARfl/fl mice, and CD4-Cre+/IFNARfl/fl mice, were
bred in-house under specific pathogen-free (SPF) conditions. All mice
were housed under SPF conditions in individually ventilated cages, in
a temperature-controlled environment with 12-h light/dark cycle,
with food and water ad libitum. All experiments were approved by
the local ethical committee for animal experiments of Ghent University
(Ghent, Belgium) (ECD17/54k).
Immunizations and Injections of mRNA-Lipoplexes
CleanCap OVA and luciferase mRNA were purchased from Trilink
Biotechnologies (respectively, L-7610 and L-7602). One microgram
of mRNA was packaged in 2 mL of Lipofectamine RNAiMAX (Life
Technologies). Packaging was performed according to the manufac-
turer’s instructions. Alternatively, the mRNA was complexed with
DOTAP/DOPE lipids in a N/P ratio (the ratio of positively-charge-
able polymer amine [N = nitrogen] groups to negatively-charged nu-
cleic acid phosphate [P]) of 1 (Avanti Polar lipids, Alabaster, AL,
USA). Ten micrograms of mRNA packed in lipoplexes was injected
i.v. (total volume of 100 mL) or s.c. at the tail base (total volume of
40 mL) in a 2-week interval.
In Vivo Imaging of IFN-b Promoter Induction
Heterozygous luciferase reporter mice (IFN-b+/Db-luc) were injected
s.c. or i.v. with 10 mg OVA-mRNA complexed with DOTAP/DOPE378 Molecular Therapy: Nucleic Acids Vol. 22 December 2020liposomes or RNAiMAX liposomes. Whole-
body radiance was measured at 0, 6, 24, 48 or
72 h after injection. The mice were sedated
andmonitored using an IVIS Lumina II imaging
system. Photon flux was quantified using theLiving Image 4.4 software (all from Caliper Life Sciences, Hopkinton,
MA, USA).
ELISpot
Two days after the second administration, mice were sacrificed and
their spleens were isolated and passed through 70-mm nylon strainers
(BD Biosciences, San Diego, CA, USA) to obtain single-cell suspen-
sions. Red blood cells were lysed using NH4Cl solution. A total of
2.5 105 cells were cultured for 24 h in wells of anti-IFN-g (Diaclone,
Besancon, France) pre-coated 96-well plates in the presence of 10 mg/
mL OVA257–264 (SIINFEKL) peptide (12-5743-82; Thermo Fisher).
Spots were analyzed according to the manufacturer’s instructions us-
ing an ELISpot reader (A. ELVIS, Hannover, Germany).
ICS and Flow Cytometry after Ex Vivo Restimulation
Two days after the second mRNA-lipoplex administration, mice were
sacrificed, their spleens were isolated aseptically, and splenocytes were
prepared. To obtain single-cell suspensions, we passed spleens
through 70-mm nylon strainers (BD Biosciences, San Diego, CA,
USA). After red blood cell lysis with NH4Cl solution, 5 105 spleno-
cytes were plated in 1 mL of culture medium (RPMI-1640 medium
supplemented with 10% fetal calf serum, 2 mM L-glutamine,
0.4 mMNa-pyruvate, nonessential amino acids, 100 U/mL penicillin,
and 0.1 mg/mL streptomycin) supplemented with OVA257–264
(SIINFEKL) peptide (12-5743-82; Thermo Fisher) at 4 mg/mL. After
6 h of peptide restimulation, 1 mL GolgiPlug (brefeldin A; BD,
Figure 4. Type I IFN Signaling on TCell Enhances the
Overall Outcome of the T Cell Response upon i.v.
Delivery of mRNA-Lipoplexes
CD11c-Cre+/IFNARfl/fl and CD4-Cre+/IFNARfl/fl mice
were immunized i.v. with 10 mg CleanCap OVA mRNA-
lipoplexes (DOTAP/DOPE or RNAiMAX). Two weeks after
the last immunization, the induced T cell responses were
determined. (A and B) Spleens were isolated and in vitro
stimulated with OVA peptide for 16 h. (A) The number of
OVA-specific IFN-g-secreting splenocytes was deter-
mined by an ELISpot. Data represent individual mice and
the mean (four or five mice per group). (B) Functionality of
OVA-specific T lymphocytes was measured by flow cy-
tometry using intracellular staining for IFN-g. Data repre-
sent individual mice and mean +/ SD (four or five mice
per group). (C) Amixture of CFSE-labeled cells pulsed with
control (CFSElow) or OVA peptide (CFSEhigh) was adop-
tively transferred in a 1:1 ratio to mRNA-lipoplex-immu-
nized mice (i.v. route). Specific killing was measured
2 days later by flow cytometry. Data represent individual
mice and the mean +/ SD (four or five mice per group).
www.moleculartherapy.orgErembodegem, Belgium) was added to 1 mL culture medium for the
measurement of cytokine production by ICS. The Cytofix/Cytoperm
kit (BD) was used according to the manufacturer’s protocol. In brief,
16 h after addition of GolgiPlug, cells were stained with a live/dead
marker (eBioscience fixable viability dye eFluor 450, 65-0866-14,
1:1,000; Thermo Fisher) and with fluorochrome-labeled antibodies
against major histocompatibility complex class II (MHC class II)
(MHC class II-eFluor450, 48-5321-82, 1:500; Thermo Fisher), CD3
(CD3-alexa fluor 488 [AF488], 557666, 1:250; BD Pharmingen),
CD4 (CD4-phycoerythrin [PE]-cy5, 561836, 1:300; BD Pharmingen),
and CD8 (CD8-PE-cy7, 25-0081-81, 1:300; Thermo Fisher). Cells
were fixed/permeabilized using the Cytofix/Cytoperm kit (BD) and
stained for IFN-g (IFN-g-allophycocyanin [APC]; 554413, 1:100;
BD Pharmingen). Cells were then analyzed using an LSR Fortessa
(BD) with FlowJo software (Tree Star, Ashland, OR, USA).
In Vivo Killing Assay
Splenocytes from naive wild-type mice were pulsed with 1 mg/mL
MHC class I OVA peptide or HIV-1 Gag peptide as a control before
labeling with 5 or 0.5 mmol/L Carboxyfluorescein succinimidyl ester
(CFSE) (Invitrogen), respectively. Labeled cells were mixed at a 1:1 ra-
tio, and a total of 1.5  107 cells were adoptively transferred into
immunized mice 2 weeks after boost. Splenocytes from host mice
were analyzed 2 days later by flow cytometry after staining with
a-F4/80 (BD Biosciences) to exclude auto-fluorescent macrophages.Percentage antigen-specific killing was determined using the
following formula: (1  (%CFSEhi cells/%CFSElow cells)treated mice/(%
CFSEhi cells/% CSFElow cells)non-treated mice)  100. The experiments
were performed on a triple-laser (B-V-R) LSR-II (Becton Dickinson,
San Jose, CA, USA) and analyzed using the FlowJo software (Tree Star).
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